Search research articles
Contact Us
Filters
Showing results (81-90 of 209) with videos related to
Page
of 21
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
February 8, 2018
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases
Clément Gauvain, Enora Vauléon, Christos Chouaid, et al.
Journal of Epidemiology and Population Health
|
March 20, 2025
Conditions réelles d'utilisation du durvalumab en France : Une étude observationnelle rétrospective des patients traités pour un cancer digestif et/ou bronchopulmonaire entre 2019 et 2023
Jérôme Fernandes, Cindy Neuzillet, Axel Benoist, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 12, 2025
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system
Christos Chouaid, Clarisse Marchal, Marion Apert, et al.
Current Oncology (Toronto, Ont.)
|
March 27, 2024
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort
Simon Nannini, Florian Guisier, Hubert Curcio, et al.
BMC Pulmonary Medicine
|
March 23, 2013
The association between asthma control, health care costs, and quality of life in France and Spain
Marianne Doz, Christos Chouaid, Laure Com-Ruelle, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 20, 2011
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain
Kurt Banz, Helge Bischoff, Matthias Brunner, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
January 8, 2020
Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy
Faustine Dalon, Gilles Devouassoux, Manon Belhassen, et al.
Clinical Lung Cancer
|
June 12, 2012
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)
Christos Chouaid, Hervé Le Caer, Romain Corre, et al.
Clinical Lung Cancer
|
October 9, 2022
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
Florian Guisier, Renaud Descourt, Helene Babey, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 30, 2007
An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study
Hervé LeCaer, Fabrice Barlesi, Gilles Robinet, et al.
Page
of 21
Search research articles
Search
Showing results (81-90 of 209) with videos related to
Sort By:
Page
of 21
Lung Cancer (Amsterdam, Netherlands)
|
February 8, 2018
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases
Clément Gauvain, Enora Vauléon, Christos Chouaid, et al.
Journal of Epidemiology and Population Health
|
March 20, 2025
Conditions réelles d'utilisation du durvalumab en France : Une étude observationnelle rétrospective des patients traités pour un cancer digestif et/ou bronchopulmonaire entre 2019 et 2023
Jérôme Fernandes, Cindy Neuzillet, Axel Benoist, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 12, 2025
Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system
Christos Chouaid, Clarisse Marchal, Marion Apert, et al.
Current Oncology (Toronto, Ont.)
|
March 27, 2024
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort
Simon Nannini, Florian Guisier, Hubert Curcio, et al.
BMC Pulmonary Medicine
|
March 23, 2013
The association between asthma control, health care costs, and quality of life in France and Spain
Marianne Doz, Christos Chouaid, Laure Com-Ruelle, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 20, 2011
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain
Kurt Banz, Helge Bischoff, Matthias Brunner, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
January 8, 2020
Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy
Faustine Dalon, Gilles Devouassoux, Manon Belhassen, et al.
Clinical Lung Cancer
|
June 12, 2012
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)
Christos Chouaid, Hervé Le Caer, Romain Corre, et al.
Clinical Lung Cancer
|
October 9, 2022
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
Florian Guisier, Renaud Descourt, Helene Babey, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 30, 2007
An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study
Hervé LeCaer, Fabrice Barlesi, Gilles Robinet, et al.
Page
of 21